{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T14:49:27Z","timestamp":1744642167217,"version":"3.28.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urolonc.2024.07.010","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T02:54:30Z","timestamp":1722135270000},"page":"451.e11-451.e18","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study"],"prefix":"10.1016","volume":"42","author":[{"given":"Seyed Hamidreza","family":"Mahmoudpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Knott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Verpillat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.07.010_bib0001","unstructured":"Global Cancer Observatory. Cancer today. Accessed: May 29, 2024.http:\/\/gco.iarc.fr."},{"key":"10.1016\/j.urolonc.2024.07.010_bib0002","unstructured":"Cancer Research UK. Bladder cancer statistics. Accessed: May 29, 2924. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bladder-cancer."},{"key":"10.1016\/j.urolonc.2024.07.010_bib0003","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0004","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. v3.2024. Accessed: May 29, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.urolonc.2024.07.010_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0006","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0007","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0008","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0009","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0011","unstructured":"National Institute for Health and Care Excellence. Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable. Technology appraisal guidance [TA739]. Accessed: May 29, 2024. https:\/\/www.nice.org.uk\/guidance\/ta739."},{"key":"10.1016\/j.urolonc.2024.07.010_bib0012","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). Technology appraisal guidance [TA674]. Accessed: May 29, 2024. https:\/\/www.nice.org.uk\/guidance\/ta674."},{"key":"10.1016\/j.urolonc.2024.07.010_bib0013","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0014","unstructured":"National Institute for Health and Care Excellence. Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. Technology appraisal guidance [TA788]. Accessed: May 29, 2024. https:\/\/www.nice.org.uk\/guidance\/ta788."},{"key":"10.1016\/j.urolonc.2024.07.010_bib0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0016","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0017","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/fon-2023-0298","article-title":"Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis","volume":"20","author":"Kearney","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: National Cancer Registration Dataset in England","volume":"49","author":"Henson","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0019","article-title":"Data resource profile: the Systemic Anti-Cancer Therapy (SACT) dataset","volume":"49","author":"Bright","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0021","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0022","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0023","article-title":"Real-world treatment patterns among an incident cohort of patients with Hodgkin lymphoma in the United States","volume":"20","author":"Szabo","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0024","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/13696998.2019.1591424","article-title":"Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma","volume":"22","author":"Aly","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2020.00167","article-title":"Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre","volume":"10","author":"Cheeseman","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2018.07.025","article-title":"Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015","volume":"16","author":"Fisher","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0027","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/fon-2018-0654","article-title":"Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study","volume":"15","author":"Flannery","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0028","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-170149","article-title":"Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States","volume":"4","author":"Galsky","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4538","article-title":"Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma","volume":"39","author":"Geynisman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0030","first-page":"32","article-title":"Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: Results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017","author":"Jensen","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.07.010_bib0031","article-title":"Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study","volume":"25","author":"Richters","year":"2020","journal-title":"Cancer Treat Res Commun"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:33:47Z","timestamp":1731746027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924005477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1078143924005477"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.07.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}